- Email: [email protected]
5629321 Bicyclic compound and platelet aggregation inhibitor containing the same
IV
Transfus. Sci. Vol. 18, No. 2 inhibiting re.occlusion without inducing a systemic effect.
EXTRACORPOREAL VIRIONCIDAL APPARATUS
5626884 TREATMENT OF SICKLE CELL DISEASE Lockett Curtis G STATES
New Orleans, LA, UNITED
A maintenance regimen with controlled intake of particular vitamin, mineral, and micronutrient formulations, drastically reduces the incidence and severity of sickle cell disease crises. The formulations include vitamin A, vitamin B-l, vitamin B-2, vitamin B-6, vitamin B-12, vitamin C, vitamin D, vitamin E, niacinamide, para-aminobenzoic acid (PABA), pantothenic acid, choline bitartrate, inositol, rutin, citrus bioflavonoid complex, betaine hydrochloride, hesperidin complex, folic acid, biotin, calcium, iron, magnesium, zinc, potassium, manganese, iodine, chromium, selenium, and a pharmaceutically acceptable carrier, provided at or just below critical saturation levels, determined for each individual by carefully monitoring tolerance on titration. The daily dose may exceed that necessary as dietary or nutritional supplements, and trigger an increase in the production of viable hemoglobin, and alters the overall blood profile. Piatelet concentration is increased up to twice that of seen in normal blood, and the red blood cells produced display increased resistance to sickling. This enhanced biosynthesis is achieved by providing sufficient stores of precursors that stimulate low level manufacture without substantial feedback control by the upper central nervous system.
5627036 USE OF AN ANTICOAGULANT A DIAGNOSTIC AGENT
5628727
Hakky Said I; Hakki A-Hamid; Hudson Perry B Largo, FL, UNITED STATES An extracorporeal radiation-therapy apparatus for use in treating the blood of a donor for diseased cells or organisms. The apparatus separates the blood by a density gradient device and treats the different blood fractions with drugs and/or high energy radiation.
5629294 COMPOSITIONS AND METHODS FOR PREVENTING ADHESION FORMATION diZerega Gere S; Rodgers Kathleen E Pasadena, CA, UNITED STATES assigned to University of Southern California Compositions and methods for prevention of adhesion formation, whereby an effective amount of one or more adhesion preventing RGD-containing peptides is administered for a period of time sufficient to permit tissue repair. The RGD-containing peptide is further characterized in that it inhibits platelet aggregation and does not induce inflammation or trauma at the site of administration. The RGD-containing peptide is preferably administered in conjunction with a delivery vehicle (e.g., microcapsules, microspheres, liposomes, viscous instillates and absorbable mechanical barriers) useful for maintaining local concentrations of the peptide at an effective level.
AS
Reutelingsperger Christiaan Maastricht, NETHERLANDS assigned to Boehringer Ingelbeim International GmbH Detectably labelled annexines and compositions thereof are disclosed. Also disclosed are methods for diagnosing a disruption or activation of the hemostatic system or a prothrombotic state in an individual suspected of having a hemostatic disorder, by contacting the blood of said individual with an annexine, and detecting whether an annexine-platelet complex is formed.
5629321 BICYCLIC COMPOUND AND PLATELET AGGREGATION INHIBITOR CONTAINING THE SAME Okumura Kunio; Yokoyama Isao; Shimazaki Toshiyuki; Miyamoto Michihiko; Yamashita Hiroyuki; Kibayashi Kenji; Yutaka Takanori; Yazawa Kouhei Chiba ken, JAPAN assigned to Mitsui Toatsu Chemicals Inc
N e w Patents
The invention relates to a novel compound which is represented by the formula and has an excellent platelet aggregation inhibiting action based on fibrinogen antagonism. The platelet aggregation inhibitor containing the compound of the formula
as an effective ingredient are effective for prevention and curing of thrombosis and restenosis or reocclusion after percutaneous transluminal coronary angioplasty or percutaneous transluminal coronary recanalization.
V
Transfus. Sci. Vol. 18, No. 2 inhibiting re.occlusion without inducing a systemic effect.
EXTRACORPOREAL VIRIONCIDAL APPARATUS
5626884 TREATMENT OF SICKLE CELL DISEASE Lockett Curtis G STATES
New Orleans, LA, UNITED
A maintenance regimen with controlled intake of particular vitamin, mineral, and micronutrient formulations, drastically reduces the incidence and severity of sickle cell disease crises. The formulations include vitamin A, vitamin B-l, vitamin B-2, vitamin B-6, vitamin B-12, vitamin C, vitamin D, vitamin E, niacinamide, para-aminobenzoic acid (PABA), pantothenic acid, choline bitartrate, inositol, rutin, citrus bioflavonoid complex, betaine hydrochloride, hesperidin complex, folic acid, biotin, calcium, iron, magnesium, zinc, potassium, manganese, iodine, chromium, selenium, and a pharmaceutically acceptable carrier, provided at or just below critical saturation levels, determined for each individual by carefully monitoring tolerance on titration. The daily dose may exceed that necessary as dietary or nutritional supplements, and trigger an increase in the production of viable hemoglobin, and alters the overall blood profile. Piatelet concentration is increased up to twice that of seen in normal blood, and the red blood cells produced display increased resistance to sickling. This enhanced biosynthesis is achieved by providing sufficient stores of precursors that stimulate low level manufacture without substantial feedback control by the upper central nervous system.
5627036 USE OF AN ANTICOAGULANT A DIAGNOSTIC AGENT
5628727
Hakky Said I; Hakki A-Hamid; Hudson Perry B Largo, FL, UNITED STATES An extracorporeal radiation-therapy apparatus for use in treating the blood of a donor for diseased cells or organisms. The apparatus separates the blood by a density gradient device and treats the different blood fractions with drugs and/or high energy radiation.
5629294 COMPOSITIONS AND METHODS FOR PREVENTING ADHESION FORMATION diZerega Gere S; Rodgers Kathleen E Pasadena, CA, UNITED STATES assigned to University of Southern California Compositions and methods for prevention of adhesion formation, whereby an effective amount of one or more adhesion preventing RGD-containing peptides is administered for a period of time sufficient to permit tissue repair. The RGD-containing peptide is further characterized in that it inhibits platelet aggregation and does not induce inflammation or trauma at the site of administration. The RGD-containing peptide is preferably administered in conjunction with a delivery vehicle (e.g., microcapsules, microspheres, liposomes, viscous instillates and absorbable mechanical barriers) useful for maintaining local concentrations of the peptide at an effective level.
AS
Reutelingsperger Christiaan Maastricht, NETHERLANDS assigned to Boehringer Ingelbeim International GmbH Detectably labelled annexines and compositions thereof are disclosed. Also disclosed are methods for diagnosing a disruption or activation of the hemostatic system or a prothrombotic state in an individual suspected of having a hemostatic disorder, by contacting the blood of said individual with an annexine, and detecting whether an annexine-platelet complex is formed.
5629321 BICYCLIC COMPOUND AND PLATELET AGGREGATION INHIBITOR CONTAINING THE SAME Okumura Kunio; Yokoyama Isao; Shimazaki Toshiyuki; Miyamoto Michihiko; Yamashita Hiroyuki; Kibayashi Kenji; Yutaka Takanori; Yazawa Kouhei Chiba ken, JAPAN assigned to Mitsui Toatsu Chemicals Inc
N e w Patents
The invention relates to a novel compound which is represented by the formula and has an excellent platelet aggregation inhibiting action based on fibrinogen antagonism. The platelet aggregation inhibitor containing the compound of the formula
as an effective ingredient are effective for prevention and curing of thrombosis and restenosis or reocclusion after percutaneous transluminal coronary angioplasty or percutaneous transluminal coronary recanalization.
V